Atea Pharmaceuticals Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $3.27
- Today's High:
- $3.34
- Open Price:
- $3.31
- 52W Low:
- $2.94
- 52W High:
- $9.79
- Prev. Close:
- $3.31
- Volume:
- 214712
Company Statistics
- Market Cap.:
- $368.21 million
- Book Value:
- 7.412
- Revenue TTM:
- $192.18 million
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $-81936000
- Profit Margin:
- 0%
- Return on Assets TTM:
- -11.99%
- Return on Equity TTM:
- -16.84%
Company Profile
Atea Pharmaceuticals Inc had its IPO on 2020-10-30 under the ticker symbol AVIR.
The company operates in the Healthcare sector and Biotechnology industry. Atea Pharmaceuticals Inc has a staff strength of 73 employees.
Stock update
Shares of Atea Pharmaceuticals Inc opened at $3.31 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $3.27 - $3.34, and closed at $3.29.
This is a -0.6% slip from the previous day's closing price.
A total volume of 214,712 shares were traded at the close of the day’s session.
In the last one week, shares of Atea Pharmaceuticals Inc have slipped by -1.79%.
Atea Pharmaceuticals Inc's Key Ratios
Atea Pharmaceuticals Inc has a market cap of $368.21 million, indicating a price to book ratio of 0.5513 and a price to sales ratio of 1.9026.
In the last 12-months Atea Pharmaceuticals Inc’s revenue was $192.18 million with a gross profit of $-81936000 and an EBITDA of $-129687000. The EBITDA ratio measures Atea Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Atea Pharmaceuticals Inc’s operating margin was 0% while its return on assets stood at -11.99% with a return of equity of -16.84%.
In Q1, Atea Pharmaceuticals Inc’s quarterly earnings growth was a positive 264.1% while revenue growth was a positive 295.2%.
Atea Pharmaceuticals Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-1.41 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Atea Pharmaceuticals Inc’s profitability.
Atea Pharmaceuticals Inc stock is trading at a EV to sales ratio of 58.974 and a EV to EBITDA ratio of -9.6769. Its price to sales ratio in the trailing 12-months stood at 1.9026.
Atea Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $638.13 million
- Total Liabilities
- $12.36 million
- Operating Cash Flow
- $24.48 million
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
Atea Pharmaceuticals Inc ended 2024 with $638.13 million in total assets and $0 in total liabilities. Its intangible assets were valued at $638.13 million while shareholder equity stood at $618.18 million.
Atea Pharmaceuticals Inc ended 2024 with $0 in deferred long-term liabilities, $12.36 million in other current liabilities, 83000.00 in common stock, $-95346000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $183.26 million and cash and short-term investments were $620.49 million. The company’s total short-term debt was $730,000 while long-term debt stood at $0.
Atea Pharmaceuticals Inc’s total current assets stands at $632.39 million while long-term investments were $0 and short-term investments were $437.23 million. Its net receivables were $0 compared to accounts payable of $700000.00 and inventory worth $0.
In 2024, Atea Pharmaceuticals Inc's operating cash flow was $24.48 million while its capital expenditure stood at $0.
Comparatively, Atea Pharmaceuticals Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $3.29
- 52-Week High
- $9.79
- 52-Week Low
- $2.94
- Analyst Target Price
- $4
Atea Pharmaceuticals Inc stock is currently trading at $3.29 per share. It touched a 52-week high of $9.79 and a 52-week low of $9.79. Analysts tracking the stock have a 12-month average target price of $4.
Its 50-day moving average was $3.47 and 200-day moving average was $3.88 The short ratio stood at 2.92 indicating a short percent outstanding of 0%.
Around 910% of the company’s stock are held by insiders while 7067.8% are held by institutions.
Frequently Asked Questions About Atea Pharmaceuticals Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase III SUNRISE-3 clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, a drug that is in Phase II clinical trial for the treatment and prophylaxis of dengue; and AT-281, a pharmaceutically acceptable salt for the treatment or prevention of an RNA viral infection, including dengue fever, yellow fever, and Zika virus, as well as Ruzasvir, an investigational NS5A inhibitor for the treatment of chronic HCV infection. It also develops a co-formulated, oral, pan-genotypic fixed dose combination of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virous (HCV); It has a license agreement with Merck & Co, Inc. development, manufacture, and commercialization of ruzasvir for the treatment of HCV. Atea Pharmaceuticals, Inc. was incorporated in 2012 and is headquartered in Boston, Massachusetts.